Category Archives: Global News Feed

ILUVIEN receives approval and pricing for non-infectious uveitis affecting the posterior segment indication in July; launch to follow ILUVIEN receives approval and pricing for non-infectious uveitis affecting the posterior segment indication in July; launch to follow

See the rest here:
Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy

- Adverum to present new best-corrected visual acuity (BCVA) data from the OPTIC Trial of ADVM-022 (ixoberogene soroparvovec) in wet AMD

Originally posted here:
Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

PRINCETON, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be participating in a virtual panel discussion presented by Maxim Group LLC and hosted by M-Vest. Full details on the panel are as follows:

Originally posted here:
Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel

BRIDGEWATER, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will attend the 12th Annual World Orphan Drug Congress USA 2022, being held at the Hynes Convention Center in Boston, on July 11-13, 2022.

Go here to see the original:
Hillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13

Key patent strengthens proprietary position in China until August 2031 Key patent strengthens proprietary position in China until August 2031

Read the original:
Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent...

TEL AVIV, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has started the process of preparing for an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for its Phase IIb clinical trial for SCI-110 in patients suffering from Tourette Syndrome ("TS").

Read the original:
SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment...

BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, announced today that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the William Blair Biotech Focus Conference 2022, which will be available to view on-demand beginning Monday, July 11, 2022. Management will be available for in-person meetings at the conference on Tuesday, July 12, 2022.

See the rest here:
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022

SEATTLE, July 08, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 3, 2022. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Follow this link:
Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022

Lille, France; Cambridge, MA; July 08, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Read more from the original source:
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

FLT180a generated protective FIX levels with no bleeding or need for FIX replacement

Read the original here:
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on...